Microbiological profile of a new topical antibacterial: retapamulin ointment 1%

References

• Afset JE, Maeland JA. Susceptibility of skin and soft-tissue isolates of Staphylococcus aureus and Streptococcus pyogenes to topical antibiotics: indications of clonal spread of fusidic acid-resistant Staphylococcus aureus. Scand. J. Infect. Dis.35(2), 84–89 (2003).
   PubMed Web of Science ®Google Scholar
• Rortveit S, Rortveit G. Impetigo in epidemic and nonepidemic phases: an incidence study over 4(1/2) years in a general population. Br. J. Dermatol.157(1), 100–105 (2007).
   PubMed Web of Science ®Google Scholar
• Shah M, Mohanraj M. High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br. J. Dermatol.148(5), 1018–1020 (2003).
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn. Microbiol. Infect. Dis.42(4), 283–290 (2002).
   PubMed Web of Science ®Google Scholar
• Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst. Rev.2, CD003261 (2004).
   Google Scholar
• Simor AE, Stuart TL, Louie L et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob. Agents Chemother.51(11), 3880–3886 (2007).
   PubMed Web of Science ®Google Scholar
• Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect. Control Hosp. Epidemiol.24(5), 342–346 (2003).
   PubMed Web of Science ®Google Scholar
• Koning S, van der Wouden JC. Treatment for impetigo. BMJ329(7468), 695–696 (2004).
   PubMed Web of Science ®Google Scholar
• Brown EM, Wise R. Fusidic acid cream for impetigo. Fusidic acid should be used with restraint. BMJ324(7350), 1394 (2002).
   Google Scholar
• Stoddart B, Collyns T, Denton M. Fusidic acid cream for impetigo. Problem may be clinically important. BMJ324(7350), 1394 (2002).
   PubMedGoogle Scholar
• Dobie D, Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch. Dis. Child.89(1), 74–77 (2004).
   PubMed Web of Science ®Google Scholar
• Koning S, van der Wouden JC, Chosidow O et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br. J. Dermatol.158(5), 1077–1082 (2008).
   PubMed Web of Science ®Google Scholar
• Oranje AP, Chosidow O, Sacchidanand S et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology215(4), 331–340 (2007).
   PubMed Web of Science ®Google Scholar
• Free A, Roth E, Dalessandro M et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. SkinMed5(5), 224–232 (2006).
   PubMedGoogle Scholar
• Parish LC, Jorizzo JL, Breton JJ et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J. Am. Acad. Dermatol.55(6), 1003–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Hoegenauer G. The mode of action of pleuromutilin derivatives. Location and properties of pleuromutilin binding site on Escherichia coli ribosomes. Eur. J. Biochem.52(1), 93–98 (1975).
   PubMedGoogle Scholar
• Hodgin LA, Hogenauer G. The mode of action of pleuromutilin derivatives. Effect on cell-free polypeptide synthesis. Eur. J. Biochem.47(3), 527–533 (1974).
   PubMedGoogle Scholar
• Yan K, Madden L, Choudhry A, Voigt C, Copeland RA, Gontarek RR. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob. Agents Chemother.50(11), 3875–3881 (2006).
   PubMed Web of Science ®Google Scholar
• Champney S, Rodgers WK. Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob. Agents Chemother.51(9), 3385–3387 (2007).
   PubMed Web of Science ®Google Scholar
• Davidovich C, Bashan A, Auerbach-Nevo T, Yaggie RD, Gontarek RR, Yonath A. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl Acad. Sci. USA104(11), 4291–4296 (2007).
   PubMed Web of Science ®Google Scholar
• Schlunzen F, Pyetan E, Fucini P, Yonath A, Harms JM. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol.54(5), 1287–1294 (2004).
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA. Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol.8(5), 534–542 (2005).
   PubMed Web of Science ®Google Scholar
• Harms JM, Bartels H, Schlunzen F, Yonath A. Antibiotics acting on the translational machinery. J. Cell Sci.116(Pt 8), 1391–1393 (2003).
   PubMed Web of Science ®Google Scholar
• Pringle M, Poehlsgaard J, Vester B, Long KS. Mutations in ribosomal protein L3 and 23S ribosomal RNA at the peptidyl transferase centre are associated with reduced susceptibility to tiamulin in Brachyspira spp. isolates. Mol. Microbiol.54(5), 1295–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Kosowska-Shick K, Clark C, Credito K et al. Single- and multistep resistance selection studies on the activity of retapamulin compared with other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother.50(2), 765–769 (2006).
   PubMed Web of Science ®Google Scholar
• Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob. Agents Chemother.51(6), 2048–2052 (2007).
   PubMed Web of Science ®Google Scholar
• Traczewski MM, Brown SD. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother.52(11), 3863–3867 (2008).
   PubMed Web of Science ®Google Scholar
• Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother.50(7), 2500–2505 (2006).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother.52(6), 2244–2246 (2008).
   PubMed Web of Science ®Google Scholar
• Toh SM, Xiong L, Arias CA et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol.64(6), 1506–1514 (2007).
   PubMed Web of Science ®Google Scholar
• Scangarella N, Jakielaszek C, McCloskey L et al. Analysis of the antibacterial activity of retapamulin against 10,595 isolates of Staphylococcus aureus, Streptococcus pyogenes and Streptococcus agalactiae from pre-clinical, global surveillance and clinical studies. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Approved Standard (15th Edition). Clinical and Laboratory Standards Institute Publication M100-S15. Clinical and Laboratory Standards Institute, PA, USA (2005).
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard (6th Edition). Clinical and Laboratory Standards Institute Publication M7-A6. Clinical and Laboratory Standards Institute, PA, USA (2005).
   Google Scholar
• Ross JE, Jones RN. Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods. J. Clin. Microbiol.43, 6212–6213 (2005).
   PubMed Web of Science ®Google Scholar
• Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob. Agents Chemother.41(5), 1137–1139 (1997).
   PubMed Web of Science ®Google Scholar
• Toma E, Barriault D. Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for Gram-positive cocci. J. Clin. Microbiol.33(7), 1712–1715 (1995).
   PubMed Web of Science ®Google Scholar
• Bouchillon S, Hoban D, Jordan A et al. Retapamulin (SB-275833), a novel pleuromutilin – a multi-center global surveillance of activity against 3797 β and α hemolytic streptococci isolated from skin and skin structure infections (SSSIs). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 21–24 September 2005.
   Google Scholar
• Stevens T, Johnson B, Bouchillon S et al. A multi-center global surveillance study of the in vitro activity of retapamulin (SB-275833), a novel topical pleuromutilin against 2950 clinical isolates of S. aureus and coagulase-negative staphylococci from uncomplicated skin and skin structure infections (SSSIs). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 21–24 September 2005.
   Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates. Antimicrob. Agents Chemother.50(1), 379–381 (2006).
   PubMed Web of Science ®Google Scholar
• Odou MF, Muller C, Calvet L, Dubreuil L. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J. Antimicrob. Chemother.59(4), 646–651 (2007).
   PubMed Web of Science ®Google Scholar
• Molitoris D, Finegold SM, Bolaños M. In vitro activity of retapamulin and five comparator agents against 226 anaerobic bacterial isolates. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 21–24 September 2005.
   Google Scholar
• Rittenhouse S, Biswas S, Broskey J et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother.50(11), 3882–3885 (2006).
   PubMed Web of Science ®Google Scholar
• Williams L, Northwood J, Crowhurst N, Felmingham D. In vitro activity of retapamulin, a novel pleuromutilin, against Staphylococcus spp. (n=1413) and Streptococcus pyogenes (n=503) form 26 European centres. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy. Munich, Germany, 17 March–3 April 2007.
   Google Scholar
• Brown SD, Traczewski MM. Retapamulin: in vitro potency, spectrum of activity, MIC and disk breakpoints. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 21–24 September 2005.
   Google Scholar
• Draghi D, Scangarella N, Shawar R, Sahm D. In vitro activity of retapamulin and comparators against 1690 recent Gram-positive clinical isolates. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 21–24 September 2005.
   Google Scholar
• Felmingham D, Williams LJ, Northwood JGE, Crowhurst NA. In vitro activity of retapamulin, a novel pleuromutilin, against Streptococcus pyogenes, Streptococcus agalactiae and ‘viridans’ streptococci isolates from 26 centers in 14 European countries. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 21–24 September 2005.
   Google Scholar
• Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob. Agents Chemother.50(7), 2583–2586 (2006).
   PubMed Web of Science ®Google Scholar
• Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Mol. Biol.330(5), 1005–1014 (2003).
   PubMed Web of Science ®Google Scholar
• Schlunzen F, Zarivach R, Harms J et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature413(6858), 814–821 (2001).
   PubMed Web of Science ®Google Scholar